[Perspective of proteomic studies for discovering biomarkers of diabetes and obesity].
The prevalence of diabetes is rapidly increasing worldwide, leading to an increasing risk of microangiopathic complications. To identify biomarkers of diabetic microangiopathy that are useful for prevention and early treatment of diabetic complications, proteomic analyses of clinical samples from diabetic patients have been performed. However, as diabetes is a systemic disease, it is difficult to define the pathologic conditions and foci causing changes in proteomic profile of clinical samples from diabetics. An approach using multiple reaction monitoring may be useful to systemically identify diabetic microangiopathy biomarkers from blood and urine samples from diabetic patients.